Moderna Inc (NASDAQ: MRNA) is -46.30% lower on its value in year-to-date trading and has touched a low of $53.05 and a high of $170.47 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRNA stock was last observed hovering at around $53.80 in the last trading session, with the day’s loss setting it -0.4%.
Currently trading at $53.40, the stock is -10.12% and -23.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.56 million and changing -0.74% at the moment leaves the stock -47.86% off its SMA200. MRNA registered -33.58% loss for a year compared to 6-month loss of -50.51%. The firm has a 50-day simple moving average (SMA 50) of $70.2734 and a 200-day simple moving average (SMA200) of $102.7105.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -16.74% gain in the last 1 month and extending the period to 3 months gives it a -54.82%, and is -6.82% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.29% over the week and 3.45% over the month.
Moderna Inc (MRNA) has around 5600 employees, a market worth around $20.53B and $5.04B in sales. Profit margin for the company is -116.36%. Distance from 52-week low is 0.66% and -68.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.28%).
with sales reaching $1.22B over the same period.The EPS is expected to grow by 21.56% this year, but quarterly earnings will post -53.00% year-over-year. Quarterly sales are estimated to shrink -33.30% in year-over-year returns.
Moderna Inc (MRNA) Top Institutional Holders
1357.0 institutions hold shares in Moderna Inc (MRNA), with institutional investors hold 79.67% of the company’s shares. The shares outstanding are 382.00M, and float is at 342.76M with Short Float at 9.14%. Institutions hold 72.09% of the Float.
The top institutional shareholder in the company is BAILLIE GIFFORD & CO with over 43.45 million shares valued at $5.16 billion. The investor’s holdings represent 11.3741% of the MRNA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 39.56 million shares valued at $$4.7 billion to account for 10.3568 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 25.56 million shares representing 6.6917% and valued at over $3.04 billion, while FMR LLC holds 5.5396 of the shares totaling 21.16 million with a market value of $2.51 billion.
Moderna Inc (MRNA) Insider Activity
The most recent transaction is an insider sale by Mock James M, the company’s Chief Financial Officer. SEC filings show that Mock James M sold 715 shares of the company’s common stock on Oct 07 ’24 at a price of $60.12 per share for a total of $42986.0. Following the sale, the insider now owns 9505.0 shares.
Moderna Inc disclosed in a document filed with the SEC on Sep 09 ’24 that Klinger Shannon Thyme (Chief Legal Officer) sold a total of 551 shares of the company’s common stock. The trade occurred on Sep 09 ’24 and was made at $73.57 per share for $40539.0. Following the transaction, the insider now directly holds 18154.0 shares of the MRNA stock.
Still, SEC filings show that on Sep 09 ’24, Klinger Shannon Thyme (Officer) Proposed Sale 551 shares at an average price of $73.57 for $40539.0. The insider now directly holds shares of Moderna Inc (MRNA).
